Keaney Timothy F sold $404K of UNM

Keaney Timothy F sold 4,300 shares of Unum Group (UNM) at $94.02 ($0.40M total) on 2026-09-10.

Original reporting
SEC EDGAR · Keaney Timothy F
Published Sep 11, 2026, 9:34 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$UNM
Neutral
medium confidence
Mentioned
$UNM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UNMNeutralLow
01

Why it matters

The disclosed sale is the first public report of this transaction, providing new data for ownership tracking.

02

Market read

A routine insider sale with modest dollar value; unlikely to move the stock significantly.

03

What to watch

Potential upcoming corporate actions or personal liquidity needs not disclosed.

Relevance 4/10Novelty 4/10Timing: filed 2026-09-11

Background

Form 4 filings disclose insider transactions; director sales are monitored for potential signals.

Company-level read

Ticker impact

$UNMNeutralMedium confidence
Context

Director Timothy Keaney sold 4,300 shares of Unum Group for $404,286 on 2026-09-10, reducing his stake to 36,502 shares.

Expected impact

Potential short‑term downward pressure of 0.5‑1% if market reacts to the sale.

Evidence & confidence

The sale size ($404k) is minor relative to Unum's market cap; director sales often have limited impact unless unusually large.

Market effects

Minimal effect on the insurance sector; insider sales are routine.

No significant regional impact.

Limited to investors tracking Unum.

Counterpoint

The sale could be unrelated to company fundamentals; investors may ignore it.

Key entities

  • Timothy Keaney

    Director of Unum Group who sold shares.

  • Unum Group

    Insurance provider (ticker UNM).

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$UNMMed

Unum Group Stocks Climb 5.19% After JPMorgan Upgrade to Overweight

Unum Group (NYSE:UNM) shares rose 5.19% to $80.74 after JPMorgan upgraded it to Overweight, lowering its price target to $90. The firm cited attractive risk/reward despite lower estimates. Unum reported a Q3 net loss of $2.65 per share due to a $853 million investment loss, but adjusted operating income was $2.20 per share. Core premiums grew 4.7%, while US sales fell 8.5%. The company expects full-year adjusted operating income of $8.30 to $8.50 per share.

$UNMHigh

Unum Group Q3 Earnings Call Highlights

Unum Group (UNM) reported Q3 earnings, noting long-term disability claims 10% above expectations, driven by behavioral health. The company is implementing double-digit rate increases and expects full-year 2026 earnings of $8.30-$8.50 per share. Unum also completed a reinsurance transaction, reducing long-term care exposure by over 40%.

$UNMMedAI 8/10

Unum Group (UNM) (Q3 2026) Earnings Call Highlights: Disability Claims Surge Weighs

Unum Group (UNM) reported Q3 2026 earnings with mixed results. Core premiums grew 5%, and the company returned $1B to shareholders. However, earnings per share of $2.20 missed expectations due to higher disability claims. The group disability benefit ratio rose to 70.6%, and the full-year EPS outlook was revised to $8.30-$8.50. Management attributed the increase in claims to behavioral health issues and expects pricing actions to address the trend.

$UNMHighAI 9/10

Why is Unum stock crashing today?

Unum Group (UNM) stock fell 18.7% to $74.03 after reporting a Q3 2026 GAAP net loss of $419.7M, revenue shortfall of $360M, and adjusted EPS decline of 21%. Barclays cut its price target to $101. The drop is attributed to reinsurance-related charges, rising disability claims, and market focus on earnings deterioration.